Akebia Therapeutics, Inc. (AKBA)
0.8734
-0.01
(-0.58%)
USD |
NASDAQ |
Oct 07, 16:00
0.8763
0.00 (0.00%)
After-Hours: 20:00
Akebia Therapeutics Profit Margin (Quarterly) : -18.13% for June 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -18.13% |
| March 31, 2026 | -16.91% |
| December 31, 2025 | -21.25% |
| September 30, 2025 | 0.92% |
| June 30, 2025 | 0.40% |
| March 31, 2025 | 10.66% |
| December 31, 2024 | -49.04% |
| September 30, 2024 | -53.54% |
| June 30, 2024 | -19.66% |
| March 31, 2024 | -55.16% |
| December 31, 2023 | 1.09% |
| September 30, 2023 | -34.46% |
| June 30, 2023 | -19.82% |
| March 31, 2023 | -67.18% |
| December 31, 2022 | -16.74% |
| September 30, 2022 | -111.0% |
| June 30, 2022 | 23.30% |
| March 31, 2022 | -101.2% |
| December 31, 2021 | -121.1% |
| September 30, 2021 | -122.1% |
| Date | Value |
|---|---|
| June 30, 2021 | -156.9% |
| March 31, 2021 | -133.0% |
| December 31, 2020 | -153.4% |
| September 30, 2020 | -99.95% |
| June 30, 2020 | -195.0% |
| March 31, 2020 | -68.66% |
| December 31, 2019 | -135.8% |
| September 30, 2019 | -59.35% |
| June 30, 2019 | -57.71% |
| March 31, 2019 | -99.66% |
| December 31, 2018 | -100.3% |
| September 30, 2018 | -48.99% |
| June 30, 2018 | -69.82% |
| March 31, 2018 | -50.99% |
| December 31, 2017 | 17.14% |
| September 30, 2017 | -56.04% |
| June 30, 2017 | -75.45% |
| March 31, 2017 | -213.5% |
| December 31, 2016 | -2.47K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Emergent BioSolutions, Inc. | -76.91% |
| Exelixis, Inc. | 33.73% |
| ADMA Biologics, Inc. | 30.40% |
| Arcutis Biotherapeutics, Inc. | 11.56% |
| Relay Therapeutics, Inc. | -23.92K% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -95.19% |
| Return on Assets | -8.25% |
| Return on Invested Capital | -12.11% |
| Gross Profit Margin (Quarterly) | 77.59% |
| Operating Margin (Quarterly) | -8.92% |
| Return on Net Operating Assets | -21.07% |